DGAP-News: Epigenomics AG: Epigenomics signs joint commercialization agreement for Epi proColon(R) in North America with Polymedco
(firmenpresse) - DGAP-News: Epigenomics AG / Key word(s): Agreement
Epigenomics AG: Epigenomics signs joint commercialization agreement
for Epi proColon(R) in North America with Polymedco
02.10.2013 / 08:00
---------------------------------------------------------------------
- Companies to join efforts in commercialization of Epi proColon(R)
- Epigenomics to provide manufacturing, medical, regulatory and strategic
marketing
- Polymedco, the US leader in CRC screening products, to contribute
logistics, sales, marketing and customer support
Berlin, Germany, and U.S.A., October 2, 2013- Epigenomics AG (Frankfurt
Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular
diagnostics company, announced today that it has entered into a joint
commercialization agreement with Polymedco Inc., a leading provider of
colorectal cancer tests in North America. Both companies will jointly
commercialize Epi proColon(R), Epigenomics' blood-based test for colorectal
cancer (CRC) screening, in North America.
Under the terms of the agreement, Polymedco will deploy its CRC dedicated
sales force and technical support staff, administration, logistics and
other support functions to ensure the optimum market introduction and
roll-out of Epi proColon(R) once the test is potentially approved by the US
Food and Drug Administration. Both parties will work jointly on the
marketing, launch and development strategies and with key payers to obtain
favorable reimbursement coverage. Epigenomics will retain the
responsibility to manufacture the product and to support it from the
medical and regulatory point of view, including activities necessary to
achieve inclusion in major cancer screening guidelines post approval. A
working group comprised of representatives of both companies will oversee
the launch and commercial roll-out and engage in activities necessary to
ensure the commercial success of the product once it becomes available to
the market. The companies agreed to a combined transfer price and profit
sharing agreement subject to minimum annual sales of test kits from
Epigenomics to Polymedco.
Thomas Taapken, CEO and CFO of Epigenomics, commented: 'We are excited to
enter into this joint commercialization agreement with Polymedco. The
significant know-how and commitment of Polymedco to the CRC screening space
will accelerate our commercial roll-out in North America. Being able to
leverage the existing and well-functioning infrastructure of Polymedco will
mean a significant time and resource advantage for Epigenomics between now
and market launch of Epi proColon(R).'
Noel Doheny, CEO of Epigenomics' US subsidiary, commented: 'Polymedco's
commitment to the CRC screening space will accelerate our commercial
roll-out in North America and will mean a significant time and resource
advantage for Epigenomics in the launch of Epi proColon(R). Being able to
work with the market leader in CRC screening products in the US will enable
us to efficiently target the right customers in order to increase screening
compliance among those 35 million people in the US who today are not
compliant to CRC screening.'
Polymedco is the largest provider of CRC screening tests in North America,
with more than USD50m in annual sales for its cancer diagnostics products.
The company's product range includes multiple platforms for automated and
manual Fecal Immunochemical Test (FIT) solutions for CRC testing. It has an
established customer base of more than 1500 laboratories, of which 100 are
major medical centers. Polymedco's staff devoted to the joint collaboration
is comprised of more than 50 specialized sales and support experts, which
target exclusively laboratories and medical centers engaged in cancer
screening and diagnostics.
Drew Cervasio, President and CEO of Polymedco, commented: 'We are very
pleased to partner with Epigenomics on the commercialization of Epi
proColon(R) and thereby to expand our dominant position in the colon cancer
screening market. We believe that the two complementary tests, Epi
proColon(R) and FIT testing solutions, will drive the highest patient
compliance for CRC screening. Our joint mission is to screen the entire
population over 50 years old on a regular basis and offering these two
different solutions will help to achieve this. This process will lead to
early detection, better patient care and saving our healthcare system
billions of dollars with the reduction of late-stage treatment'
- Ends -
Contact Epigenomics AG
Antje Zeise, Manager IR | PR
Epigenomics AG
Kleine Praesidentenstrasse1
10178 Berlin
Tel +49 (0) 30 24345 386
ir(at)epigenomics.com
www.epigenomics.com
For US press inquiries:
Epigenomics, Inc.
9700 Great Seneca Highway Rockville
Maryland 20850
pr(at)epigenomics.com
About Epigenomics
Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer earlier
and more accurately, leading to improved outcomes for patients.
Epigenomics' lead product, Epi proColon(R), is a blood-based test for the
early detection of colorectal cancer, which is currently marketed in Europe
and is in development for the U.S.A. The Company's technology and products
have been validated through multiple partnerships with leading global
diagnostic companies and testing laboratories. Epigenomics is an
international company with operations in Europe and the U.S.A.
About Polymedco
Polymedco Inc. is a leading manufacturer, marketer, and distributer in the
clinical laboratory marketplace. Polymedco supplies clinical diagnostic
test kits and devices that are specialized in hematology and cancer. We are
a world leader in non-invasive colorectal cancer screening technology,
providing the new standard of care with the OC-Auto(R) and OC-Light(R)
product line.
Since 1980, Polymedco has evolved into a highly skilled and successful
marketing, sales, and manufacturing organization. With an experienced team
of field representatives combined with strong technical service personnel,
Polymedco provides a high level of customer, technical and reimbursement
support.
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events
or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.
End of Corporate News
---------------------------------------------------------------------
02.10.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir(at)epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
233011 02.10.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.10.2013 - 08:00 Uhr
Sprache: Deutsch
News-ID 301995
Anzahl Zeichen: 10950
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 327 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Epigenomics AG: Epigenomics signs joint commercialization agreement for Epi proColon(R) in North America with Polymedco"
steht unter der journalistisch-redaktionellen Verantwortung von
Epigenomics AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
